Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424759 | 0.90 | CYP19A1 (0.36) | KDM4ELMNASOSTCYP19A1NQO2 | |
| SCHEMBL29565868 | 0.90 | CYP19A1 (0.36) | KDM4ELMNASOSTCYP19A1NQO2 | |
| SCHEMBL28341 | 0.90 | CYP19A1 (0.36) | KDM4ELMNASOSTCYP19A1NQO2 | |
| SCHEMBL30393960 | 0.89 | CYP19A1 (0.35) | KDM4ELMNASOSTCYP19A1NQO2 | |
| SCHEMBL25448348 | 0.86 | CYP19A1 (0.33) | KDM4ELMNASOSTCYP19A1NQO2 | |
| Acetic Acid SCHEMBL29538014 | 0.83 | TARBP2 (0.34) | KDM4ELMNACYP19A1NQO2POLB | |
| SCHEMBL18810594 | 0.82 | POLB (0.33) | KDM4ELMNACYP19A1NQO2ACHE | |
| SCHEMBL1144617 | 0.81 | CYP19A1 (0.33) | CYP19A1NQO2 | |
| SCHEMBL31650843 | 0.80 | — | — | |
| SCHEMBL18187041 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376447-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065400-A1 | Transfer Hydrogenation of Cyclopamine Analogs | HVCN1, KCNQ4, KCNQ5 | KDM4E 1043/4885LMNA 4784/4885SOST 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.